Press release
Frontotemporal Dementia Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Frontotemporal Dementia Pipeline
"Frontotemporal Dementia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Frontotemporal Dementia Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Frontotemporal Dementia Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Frontotemporal Dementia Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Frontotemporal Dementia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Frontotemporal Dementia Therapeutics Domain:
https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
- Sortilin inhibitors
- Progranulin protein replacements
- Immunomodulators
- RNA interference
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Frontotemporal Dementia Therapeutics Analysis
Companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia. There are approx. 20+ key companies developing therapies for Frontotemporal Dementia.
Currently, Alector is leading the therapeutics market with its Frontotemporal Dementia drug candidates in the most advanced stage of clinical development.
Key Companies in the Frontotemporal Dementia Therapeutics Market Include:
- Alector
- Prevail Therapeutics
- Passage Bio, Inc.
- TauRx Pharmaceuticals
- Wave Life Sciences Ltd.
- CAMP4 Therapeutics
- Coya Therapeutics
- Alkermes
- DEEP GENOMICS
- Sangamo Therapeutics
- LOCANABIO
- Arkuda Therapeutics
- AZTherapies
- Yumanity
- Autifony Therapeutics
- Prothena
And Many Others
Frontotemporal Dementia Emerging and Marketed Drugs Covered in the Report Include:
- PR 006 : Prevail Therapeutics
- Latozinemab : Alector
- PBFT 02 : Passage Bio
- WVE 004 : WaVe life Sciences
- EXO 050 : Coya Therapeutics
- NI308: Neurimmune
- Research programme: CNS therapeutics: CAMP4 Therapeutics
- Research Programme: M1 PAM: Asceneuron SA
- AS-203: AcuraStem
- DNL593(PTV:PRGN): Denali Therapeutics Inc.
- PBFT02: Passage Bio, Inc.
- PR006: Prevail Therapeutics
- TPN-101: Transposon Therapeutics
- AL001: Alector Inc.
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Frontotemporal Dementia Current Treatment Patterns
4. Frontotemporal Dementia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Frontotemporal Dementia Late-Stage Products (Phase-III)
7. Frontotemporal Dementia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Frontotemporal Dementia Discontinued Products
13. Frontotemporal Dementia Product Profiles
14. Frontotemporal Dementia Key Companies
15. Frontotemporal Dementia Key Products
16. Dormant and Discontinued Products
17. Frontotemporal Dementia Unmet Needs
18. Frontotemporal Dementia Future Perspectives
19. Frontotemporal Dementia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ https://www.delveinsight.com/consulting/partner-identification-services
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies here
News-ID: 2955318 • Views: …
More Releases from DelveInsight Business Research
Autistic Disorder Pipeline 2025: In-depth Clinical Trials Analysis and Emerging …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Autistic Disorder pipeline constitutes 25+ key companies continuously working towards developing 25+ Autistic Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Autistic Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Hypovolemic Shock Market Growth to Accelerate in Forecast Period (2024-2032), De …
The Hypovolemic Shock market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypovolemic Shock pipeline products will significantly revolutionize the Hypovolemic Shock market dynamics.
DelveInsight's "Hypovolemic Shock Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hypovolemic Shock, historical and forecasted epidemiology as well as the Hypovolemic Shock market trends in the United…
Chronic Insomnia Market to Expand Significantly by 2034, States DelveInsight Rep …
The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.
DelveInsight's "Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States,…
Chronic Spontaneous Urticaria Market Growth Projections 2024-2034: DelveInsight …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria…
More Releases for Frontotemporal
Frontotemporal Dementia (FTD) Market to Reach USD 4.3 Billion by 2034
Frontotemporal Dementia (FTD) is a rare yet serious group of neurodegenerative disorders characterized by progressive damage to the frontal and temporal lobes of the brain. Unlike Alzheimer's disease, FTD often manifests earlier in life, typically between the ages of 40 and 65, and is marked by personality changes, impaired judgment, and language difficulties. Its early onset and challenging diagnosis make it one of the most complex forms of dementia to…
Frontotemporal Dementia Market Set to Double by 2034, Reaching USD 4.2 Billion
The global FTD market was valued at USD 2.1 billion in 2024 and is projected to reach USD 4.2 billion by 2034, growing at a CAGR of 7.1%. Rising diagnosis rates, growing investment in neurodegenerative disease research, and expanded healthcare access are driving this growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70788
Key Market Highlights
• Increasing recognition of FTD as distinct from Alzheimer's and other dementias.
• Expanding pipeline of clinical trials…
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569
This latest report researches the industry structure,…
Frontotemporal Dementia Treatment Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Frontotemporal Dementia Treatment Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies…
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
